Drug Trial Radar · NCT03015207
First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity
Last checked: Nov 19, 2026Latest source record: Sep 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Jan 6, 2017
Primary completion
Oct 26, 2017
Study completion Oct 26, 2017
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jan 9, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Single group
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Male only, from 22 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted in The United States of America. The aim of this trial is to investigate Safety, Tolerability and Pharmacokinetics (the exposure of the trial drug in the body) of NNC0194-0499 in Male Subjects with Overweight or Obesity.
Conditions
- Metabolism and Nutrition Disorder
- Obesity
Interventions
NNC0194-0499Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of treatment-emergent adverse events (TEAEs)Time frame: From time of administration of NNC0194-0499 (day 1) to completion of the post-treatment period at follow-up (day 36)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.